Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioblastoma × belinostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Lymphoma, T-Cell, Peripheral 6 Lymphoma, T-Cell, Cutaneous 5 Lymphoma, Non-Hodgkin 5 Lymphoma 5 Leukemia, Myeloid, Acute 5 Carcinoma, Non-Small-Cell Lung 5 Breast Neoplasms 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, T-Cell 4 Lymphoma, Large-Cell, Anaplastic 4 Lymphoma, Large B-Cell, Diffuse 4 Lung Neoplasms 4 Hodgkin Disease 4 Hematologic Neoplasms 4 Urinary Bladder Neoplasms 3 Sarcoma 3 Recurrence 3 Neoplasms 3 Myelodysplastic Syndromes 3 Mycosis Fungoides 3 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Immunoblastic Lymphadenopathy 3 Fallopian Tube Neoplasms 3 Burkitt Lymphoma 3 Waldenstrom Macroglobulinemia 2 Thyroid Neoplasms 2

Interventions

Temozolomide 362 Radiotherapy 181 Bevacizumab 142 Radiation 70 Magnetic Resonance Spectroscopy 60 Lomustine 43 pembrolizumab 37 Irinotecan 37 Carmustine 37 Surgical Procedures, Operative 34 Nivolumab 27 Carboplatin 25 Specimen Handling 23 Radiosurgery 23 Erlotinib Hydrochloride 23 Radiotherapy, Intensity-Modulated 20 Chemotherapy, Adjuvant 20 Aminolevulinic Acid 19 Cyclophosphamide 18 Drug Therapy 17 sargramostim 16 O(6)-benzylguanine 14 Radiotherapy, Conformal 13 Granulocyte-Macrophage Colony-Stimulating Factor 13 Everolimus 12 temsirolimus 11 Vorinostat 11 Sunitinib 11 Imatinib Mesylate 11 Etoposide 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02137759 2023-05-06

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Emory University

Phase 2 Unknown

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡